On August 12, 2026, Omeros Corporation's Board of Directors increased its size to nine members and appointed Joseph Schocken as a director, effective immediately. Mr. Schocken will serve until the 2027 annual meeting and was also appointed to the Audit Committee. He is the founder of Tranceka Capital LLC and former CEO of Broadmark Realty Capital, Inc. As part of his appointment, he received a stock option for 30,000 shares under the company's non-employee director compensation policy. Omeros Corporation operates in the biopharmaceutical industry, focusing on the development of therapies for inflammatory diseases.

Omeros Corporation reported financial results for the second quarter ended June 30, 2026. YARTEMLEA gross revenues increased 190% to $32.2 million, with net revenue of $28.5 million. GAAP net income was $13.2 million ($0.18 per share), excluding an $11.5 million non-cash gain from convertible note derivatives; adjusted net income was $1.8 million ($0.02 per share). The company held $132.0 million in cash and short-term investments. In July, Omeros repurchased $30.5 million of its 2029 Notes for $60.2 million, reducing outstanding principal to approximately $40.3 million and eliminating $8.6 million in future interest payments. Additionally, the company retired 0.5 million shares of common stock during the quarter at an average cost of $11.70 per share. Omeros is a biotechnology company that discovers and develops therapeutics for complement-mediated diseases, cancers, and addictive disorders.

On July 20, 2026, Omeros Corporation completed the repurchase of approximately $14.5 million in aggregate principal amount of its 9.50% Convertible Senior Notes due 2029 for a total purchase price of approximately $29.0 million, including accrued interest. This follows a previous repurchase of $16.0 million in principal, bringing the total repurchased and retired amount to $30.5 million. Approximately $40.3 million in principal amount of the Notes remains outstanding. The company is a biopharmaceutical company that develops therapeutic drugs.

Omeros Corporation expects to complete a $31.3 million repurchase of $16.0 million in aggregate principal amount of its 9.50% Convertible Senior Notes due 2029 on July 6, 2026. Additionally, the Company entered into new agreements on July 2, 2026, to repurchase up to $14.5 million in aggregate principal amount of additional Notes for a total purchase price of up to $31.0 million, expected to close between July 20 and July 30, 2026. Omeros Corporation is a biopharmaceutical company focused on developing and commercializing therapeutic solutions for ocular and inflammatory diseases.

Omeros Corporation entered into agreements to repurchase up to $16.0 million in aggregate principal amount of its 9.50% Convertible Senior Notes due 2029 for a total purchase price of up to $34.0 million. The repurchases are expected to close between July 6, 2026, and July 16, 2026, and would leave approximately $54.8 million in outstanding principal amount of Notes. Omeros Corporation is a biopharmaceutical company focused on developing and commercializing therapeutic solutions for inflammatory and inflammatory-related diseases.